John Jesitus is a medical writer based in Westminster, CO.

Articles

A steady stream of novel therapeutic agents is now navigating the atopic dermatitis (AD) pipeline.

Pipeline of Promise for Atopic Dermatitis

Armand Butera is the assistant editor for 

. He attended Fairleigh Dickinson University and graduated with a degree in communications with a concentration in journalism. Prior to graduating, Armand worked as the editor-in-chief of his college newspaper and a radio host for WFDU. He went on to work as a copywriter, freelancer, and human resources assistant before joining 

. In his spare time, he enjoys reading, writing, traveling with his companion and spinning vinyl records. Email him at 

Investigators added that the meaning of each laboratory marker is dependent on the drug that is being used for treatment.

Laboratory Markers Aid in Evaluating Atopic Dermatitis

NEA’s Eczema Expo highlights new drugs, steroid withdrawal, alternative therapies.  

New Frontiers Open for AD, Eczema Solutions

Morgan Petronelli is an associate editor for 

and joined the MJH Life Sciences team in December 2019. She graduated from Youngstown State University in 2019 with a bachelor's degree in journalism and a minor in political science. Prior to graduating, Morgan worked as the editor-in-chief of her college newspaper. She went on to work as an assignment editor at a broadcast news station in Youngstown, Ohio before joining 

She enjoys working out, listening to music, and playing with her dog Scout. You can reach her at 

Incyte announced the FDA has approved its topical selective Janus kinase (JAK)1/JAK2 inhibitor ruxolitinib (Opzelura) for the treatment of mild to moderate atopic dermatitis. 

FDA Approves Ruxolitinib for Atopic Dermatitis 

and joined the MJH Life Sciences team in April 2021. She graduated from Kent State University in 2018 with a bachelor's degree in journalism and a minor in sociology. Linda used to work as a creative writer for 

 and was a technical writer/regulatory specialist/purchasing agent at GM Industrial before coming on to the team. She enjoys reading, traveling, and learning new perspectives. You can reach her at 

Verrica Pharmaceuticals has received a complete response letter from the FDA identifying deficiencies at a manufacturing facility for VP-102. 

Verrica Pharmaceuticals Receives Response from the FDA

Derm-Biome’s topical compounds have positive results in preclinical trial. 

Derm-Biome Announces Positive Preclinical Data in AD trials

Dermavant has announced it has dosed the first patient in its phase 3 trial evaluating tapinarof cream for the treatment of moderate to severe atopic dermatitis.  

Dosing Starts in Tapinarof AD Trials

A recent phase 3 trial investigated the safety of dupilumab as a treatment for severe atopic dermatitis in pediatric patients ages 6 to 11 years. 

Safety Study Evaluates Dupilumab in Pediatric Patients with Severe AD

A new study sheds light on some of the atopic disease risks that are associated with early childhood and continue into midlife.

Investigators Reveal Subtypes in Atopic Dermatitis Disease Activity

Podcasts

Mark Lebwohl, MD, takes a deep dive in the recent delay in approval for multiple JAK inhibitor drugs for treatment of inflammatory skin conditions such as psoriasis and atopic dermatitis. He also discusses the impact of the delay, as well as the benefits of JAK inhibitors for inflammatory skin diseases, and an outlook for the future of this drug class.